Search
Jefferies London: Protagonist Therapeutics CEO Dinesh Patel responds to takeout speculation and discusses the company's programs and culture of partnering
He covers the company's oral IL-23 (partnered with JNJ), rusfertide (partnered with Takeda), and a new early stage obesity program. Coverage brought to you by
Nov 18
Stephenson Harwood lawyers discuss the keys to success for deal and partnering negotiations at London Life Science Week and beyond
Alexandra Pygall, Naomi Leach, Kristian Shearsby, and James Gubbins discuss best practices to get the most out of your deals. Brought to you by
Nov 18
Jefferies London: BeOne Medicines announced a phase 3 success for its HER2 bispecific today in gastric cancer. John Oyler walks us through that and the whole pipeline
He hit on earnings, the HER2, degraders, and what BeOne is looking for in potential partners. Coverage brought to you by
Nov 17
Jefferies London: Sofinnova Partners announced a new $750M fund XI today that will invest in early stage companies in biotech
Chairman and Managing Partner Antoine Papiernik tells us about the fund and how he expects to deploy it. Plus, the current state of European biotech. Coverage brought to you by
Nov 17
Jefferies London: Jefferies M&A Banker Chris Roop shares his take on the environment for deals in biotech
He expects deals to continue in 2026, and says that the bidding wars we have seen recently are likely deal specific. Coverage brought to you by
Nov 17
Legend Biotech CEO Ying Huang shares a post-earnings update from the company's new R&D Center in Philadelphia
He describes how Legend is no longer capacity constrained for it's CAR-T treatment, Carvykti, and previews the upcoming ASH conference.
Nov 13
Biotech CEO Sisterhood: Stealth BioTherapeutics' CEO Reenie McCarthy describes the fortitude and close relationship with a patient community that led to the first approved therapy for Barth Syndrome
Interviewed by Sisterhood editorial board member Erika Smith, Reenie McCarthy discusses how working with the Barth Syndrome Community, an ultra rare disease, helped the company better understand outcomes that are important to daily life for these patients. She also highlights the role that mitochondria play in biology, and the future of treatments for diseases of mitochondrial dysfunction. Biographies Reenie McCarthy is the Chief Executive Officer, President and a member of t
Nov 13
Apogee will have at lest four key trial readouts for its half-life optimized IL-13 program next year, including monotherapy trials and in combination with OX40L and TSLP.
CEO Michael Henderson walks us through what will be a busy year for the company. Coverage brought to you by
Nov 12
Avalo Therapeutics is developing a high affinity IL-1β for hidradenitis suppurativa - key phase 2 data will come next year
CEO Garry Neil describes the target and how he believes Avalo's therapy has especially high affinity. Approximately 1% of the population is believe to have HS. Coverage brought to you by
Nov 12
Stifel's Head of Global Equity Capital Markets Seth Rubin describes the investor feedback he is hearing about the sector lately, and the fundraising environment for companies
He says that investors are placing fewer, but larger bets on companies lately, and he expects a 'healthy' IPO market in 2026. Coverage brought to you by
Nov 12
Sionna Therapeutics is trying to improve the treatment paradigm for cystic fibrosis by targeting NBD1, a nucleotide binding-domain of the CFTR protein, and restore healthy function for more
CEO Mike Cloonan describes the unmet need for better treatments that exists today in CF, and discusses Sionna's development plans. Coverage brought to you by
Nov 12
Stifel's I&I expert Alex Thompson shares his take on the environment and, discusses names he covers that have key catalyst events
He comments on Kymera, Apogee, Avalo, Veridian, Moonlake, Spyre, and Oruka. Coverage brought to you by
Nov 12
Celcuity released what it believes is practice changing breast cancer data with its multi-target PAM inhibitor. Co-Founder & CEO Brian Sullivan describes why he believes the data is so important
He discusses the pathway and gedatolisib's ability to cover it holistically. Plus, future plans for filing and additional data in breast cancer and beyond. Coverage brought to you by
Nov 11
Stifel's Tim Opler discusses how the sector's recent rally is affecting things on the investment banking side
He comments on IPOs, fundraising, M&A, and China. Coverage brought to you by
Nov 11
Spyre Therapeutics is developing a basket of therapies (α4β7, TL1A, and IL-23) that are meant to have a greater half-life and work better in combination than current therapies for IBD and rheumatology
CEO Cameron Turtle describes the improvements Spyre is making in its therapies. 2026 is going to be a data rich year for IBD. Coverage brought to you by
Nov 11
Vicore Pharma is leveraging its understanding of the Renin-Angiotensin System (RAS) to develop angiotensin II type 2 receptor agonists for IPF and beyond
CEO Ahmed Mousa walks us through the sciences and describes how data stacked up against a synthetic external control that was presented at a medical meeting this summer. Coverage brought to you by
Nov 11
The early part of 2026 is going to be a key time for REGENXBIO's gene therapies, with an FDA decision date scheduled for Hunter's Syndrome and a pivotal trial readout in DMD
CEO Curran Simpson describes REGENXBIO's expertise in AAV, and walks us through the company's programs. Coverage brought to you by
Nov 11
Aardvark Therapeutics' approach to obesity is to inhibit hunger (vs appetite). It has a key pivotal trial scheduled to read in Prader-Willi syndrome next year, and is also working on weight loss
Founder and CEO Tien Lee describes how Aardvark's approach focuses on the gut-brain axis. Coverage brought to you by
Nov 11
Stifel's Head of Therapeutics Research Paul Matteis shares his take on the sector and discusses names he covers that have key catalyst events
He shares his thoughts on uniQure, Xenon, Alkermes, Compass Pathways, GH Research MindMed, and Dyne. Coverage brought to you by
Nov 11
Upstream Bio is focused on the TSLP space, and has a unique approach of targeting the receptor as opposed to the ligand. It might give them a better dosing and efficacy profile.
CEO Rand Sutherland describes TSLP pathway and Upstream's choice to hit the receptor, and how this could define the company's competitive profile. Coverage brought to you by
Nov 11
.png){kind=logo}
